title: Advances in the Microbiome: Applications to Clostridium difficile Infection.
abstract: Clostridium difficile is a major cause of morbidity and mortality worldwide, causing over 400,000 infections and approximately 29,000 deaths in the United States alone each year. C. difficile is the most common cause of nosocomial diarrhoea in the developed world, and, in recent years, the emergence of hyper-virulent (mainly ribotypes 027 and 078, sometimes characterised by increased toxin production), epidemic strains and an increase in the number of community-acquired infections has caused further concern. Antibiotic therapy with metronidazole, vancomycin or fidaxomicin is the primary treatment for C. difficile infection (CDI). However, CDI is unique, in that, antibiotic use is also a major risk factor for acquiring CDI or recurrent CDI due to disruption of the normal gut microbiota. Therefore, there is an urgent need for alternative, non-antibiotic therapeutics to treat or prevent CDI. Here, we review a number of such potential treatments which have emerged from advances in the field of microbiome research.
authors.affiliation: Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork, Ireland. eamonn.culligan@cit.ie.
authors.forename: Eamonn P
authors.initials: EP
authors.lastname: Culligan
authors.affiliation: Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork, Ireland. roy.sleator@cit.ie.
authors.forename: Roy D
authors.initials: RD
authors.lastname: Sleator
keywords: Clostridium difficile; antibiotic resistance; bacteriocin; faecal microbiota transplantation (FMT); genome sequencing; gut microbiota; human gut microbiome; nanopore sequencing; probiotics; synthetic biology